Published

631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: The international journal of neuropsychopharmacology
Date: 2025-08-01
Source: Europe PMC
DOI: Unavailable
PubMed: Unavailable

Authors

G Martinotti C Cavallotto G D'Andrea A D'Attilio G Mammarella F Zoratto M Pettorruso

Watch author

Derived topics and classifications

psilocybin Depression Treatment-Resistant Depression Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative reviewClinical Neuropsychopharmacology and Addiction · 2025-09-24 Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.Translational psychiatry · 2025-10-31 Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.Psychiatry research · 2025-10-01 Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health careTranslational Psychiatry · 2026-06-23